Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures

Shannon W. Finks, Paul P. Dobesh, Toby C. Trujillo, George H. Crossley

Research output: Contribution to journalReview article

1 Scopus citations


As direct oral anticoagulants (DOACs) have demonstrated favorable efficacy and safety outcomes compared with vitamin K antagonists for the treatment and prevention of venous thromboembolism and the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, their role in the management of anticoagulation during electrophysiological procedures continues to evolve. At present, guidelines are limited regarding specific recommendations for the use of DOACs in these clinical settings. Here, we review available data regarding the risks and benefits associated with various periprocedural anticoagulation management approaches when patients receiving DOACs undergo electrophysiologic procedures including cardioversion, ablation, and device implantation. This discussion is intended to provide clinicians with an overview of available evidence and best practices to minimize the risk of both thromboembolic and bleeding events in the periprocedural setting.

Original languageEnglish (US)
Pages (from-to)245-254
Number of pages10
JournalCardiology in review
Issue number5
StatePublished - Sep 1 2018


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this